TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Visualisation of the Central Analgesic Effect of Paracetamol in Functional MRI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* - Healthy volunteers~* Aged at last 18 years and over 60 years~* Male~* Non-smoking subject~* Fasting coffe, tea, coca-cola or other stimulant products since the last evening~* Subject free of any treatment within 7 days prior to inclusion including no use of analgesics or anti-inflammatory treatments~Exclusion Criteria:~* Contraindications to the administration of paracetamol~* Contraindications to the completion of MRI~* Medical history and/or surgical judged by the investigator as being incompatible with the test~* Progressive disease at the inclusion

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- paracetamol (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Documentation of HIV-1 infection, by either two positive ELISAs or two discrepant ELISAs with a confirmatory positive Western Blot~ 2. Documentation of prior HSV-2 infection by Focus Kalon ELISA~ 3. Absolute CD4+ T-cell count of greater than or equal to 300 and less than or equal to 400 cells/microliter within 30 days prior to randomization~ 4. All participants must be receiving Cotrimoxazole prophylaxis as part of standard care unless contraindicated~ 5. Age at least 18 years and above~ 6. Laboratory values (within 30 days prior to randomization)~     1. Aspartate transaminase (AST) no more than five times the upper limit of normal (ULN)~    2. Total bilirubin no more than 2 times ULN~    3. Creatinine no more than 2.0 mg/dL~    4. Platelet count at least 50 000/microliter~    5. Hemoglobin at least 8g/dL~ 7. Written informed consent~EXCLUSION CRITERIA:~1. Concurrent malignancy or any other disease state requiring cytotoxic chemotherapy~2. Symptomatic for significant HIV-related illnesses (WHO stage III or IV), such as opportunistic infections and malignancies other than mucocutaneous Kaposi's sarcoma. A history of AIDS defining opportunistic infections other than mucocutaneous Kaposi's sarcoma or candida or treated tuberculosis~3. Active HSV-2 disease as suggested by painful genital ulcer disease at time of screening or enrollment~4. Current use of antiretroviral medications or Preventing Mother-to-Child Transmission (PMTCT) use of antiretrovirals within the previous 6 months~5. Significant cardiac, pulmonary, kidney, rheumatologic, gastrointestinal, or CNS disease as detectable on routine medical history, physical examination, or screening laboratory studies.~6. Psychiatric illness that, in the opinion of the PI, might interfere with the study compliance.~7. Active substance abuse or history of prior substance abuse that may interfere with protocol compliance or patient safety.~8. CD4+ count less than 300 or more than 400 cells/microliter.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Acyclovir 400mg tablet twice daily (Type: ACTIVE_COMPARATOR): None
- Placebo tablet twice daily (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: What Matters Most: Choosing the Right Breast Cancer Surgery for You

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Assigned female at birth;~* 18 years and older;~* Confirmed diagnosis (via biopsy) of early stage breast cancer (stages I-IIIA);~* Eligible for both breast-conserving surgery and mastectomy based on medical records and clinician's opinion before surgery;~* Spoken English, Spanish, or Mandarin Chinese.~Exclusion Criteria:~* Transgender men and women;~* Women who have undergone prophylactic mastectomy;~* Women with visual impairment;~* Women with a diagnosis of severe mental illness or severe dementia;~* Women with inflammatory breast carcinoma.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Option Grid (Type: EXPERIMENTAL): Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
- Arm 2: Picture Option Grid (Type: EXPERIMENTAL): Patients in this arm will receive the Picture Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
- Arm 3: Usual Care (Type: NO_INTERVENTION): In the usual care arm, surgeons provided their standard information about breast cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Chronic plaque-type psoriasis diagnosed for at least 6 months~* Moderate to severe psoriasis as defined by: PASI score of ≥12, IGA score of ≥3, BSA (body surface area) affected by plaque-type psoriasis of ≥10%~* Chronic plaque-type psoriasis considered inadequately controlled by: topical treatment and/or; phototherapy and/or previous systemic therapy~Exclusion criteria:~* Forms of psoriasis other than chronic plaque-type~* Evidence of skin conditions at the time of the screening visit (e.g., eczema) that would interfere with evaluations of the effect of the investigational product on psoriasis~* History or evidence of active tuberculosis or evidence of latent tuberculosis (or other infections like Hepatitis-C/B), malignancy; active or known use of other immunosuppressive drugs (for eg: AIDs, RA, organ rejection etc.) at the screening visit~* Pregnant or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): placebo
- secukinumab (Type: EXPERIMENTAL): secukinumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Children suffering from primary nocturnal enuresis with no organic pathology.~* Children of either sex, not below 5 and not above 15 years of age (not below 6 years in The Netherlands and France).~* Children with a minimum of 6 wet nights in 2 weeks.~Exclusion criteria:~* Children who have previously been treated with desmopressin or other medications for nocturnal enuresis or enuresis alarms.~* Children receiving substances that are known or suspected to potentiate antidiuretic hormone, e.g. SSRI, tricyclic antidepressant drugs, chlorpromazine and carbamazepine.~* Diagnosed renal diabetes insipidus or central diabetes insipidus with an AVP (arginine vasopressin) deficiency.~* Proven urinary tract infection within the past month or a documented positive urine culture at the start of the study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is willing and able to complete the micturition diary and questionnaires correctly~* Patient has symptoms of overactive bladder (OAB) for ≥ 3 months~* Patient must experience frequency of micturition on average ≥ 8 times per 24-hour period during the 3-day micturition diary period~* Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence during the 3-day micturition diary period~Exclusion Criteria:~* Patient is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control~* Patient has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor~* Patient is using medications intended to treat OAB~* Patient has an indwelling catheter or practices intermittent self-catheterization~* Patient has diabetic neuropathy~* Patient has evidence of urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs~* Patient receives non-drug treatment including electro-stimulation therapy~* Patient has severe hypertension~* Patient has participated in a clinical study within 30 days, or had participated in any previous study with mirabegron~* Patient had an average total daily urine volume \> 3000 mL as recorded in the 3-day micturition diary period~* Patient has serum creatinine of \>150 μmol/L, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x upper limit of normal range (ULN), or gamma-glutamyl transpeptidase (γ-GT) \> 3x ULN~* Patient has a clinically significant abnormal electrocardiogram (ECG)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching mirabegron placebo tablets orally once a day for 12 weeks.
- Mirabegron 25 mg (Type: EXPERIMENTAL): Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.
- Mirabegron 50 mg (Type: EXPERIMENTAL): Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: - Male or female, 1 year above or equal to age below 18 years at the time of signing informed consent and below 18 years at the time of randomisation - Diagnosed with type 1 diabetes mellitus (based on clinical judgement and supported by laboratory analysis as per local guidelines) - Ongoing daily treatment with a basal-bolus insulin regimen using basal insulin analogue or Neutral Protamine Hagedorn (NPH) insulin for at least 90 days prior to the screening visit - HbA1c (glycosylated haemoglobin) below or equal 9.5% (80 mmol/mol) analysed by the central laboratory at the screening visit Exclusion Criteria: - More than one episode of diabetic ketoacidosis requiring hospitalisation within the last 90 days prior to the screening visit - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before screening

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Meal-time faster-acting insulin aspart and insulin degludec (Type: EXPERIMENTAL): None
- Meal-time NovoRapid® (insulin aspart) and insulin degludec (Type: ACTIVE_COMPARATOR): None
- Post-meal faster-acting insulin aspart and insulin degludec (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age 40-95 years at screening~* Current or former smoker with a history of at least 10 pack-years of cigarette smoking~* Current clinical diagnosis of COPD, with COPD symptoms \> 1 year prior to screening, as defined by GOLD criteria or other current guidelines~* COPD Severity defined by FEV1/FVC ratio \<0.70 and FEV1 \<80% of predicted normal value at screening and at randomisation~* COPD treatment with rescue medication only, or stable dose of maintenance monotherapy (LAMA, LABA or ICS), or stable dose of double maintenance therapy (LAMA/LABA or ICS/LABA), for one month prior to screening~* COPD Assessment Test (CAT) score ≥10 at randomisation~* Documentation of a chest x-ray (as per local practice) or computed tomography (CT) within 6 months prior to screening, with no clinically significant pulmonary abnormalities other than related to COPD~Exclusion criteria:~* Respiratory disease other than COPD, including:~* Current diagnosis of asthma~* Alpha-1 Antitrypsin Deficiency as the cause of COPD~* Other respiratory disorders and conditions as listed in the protocol~* Severe COPD exacerbation (resulting in hospitalisation) not resolved within 8 weeks prior to screening, or moderate exacerbation not resolved within 4 weeks, or during screening~* Pneumonia or lower respiratory tract infection that required antibiotics within 8 weeks prior to screening, or during screening.~* Significant diseases or conditions other than COPD which may put the patient at risk, or influence the results of the study or the patient's ability to participate, including cardiac disease, advanced renal disease, and cancer that has not been in complete remission for at least 5 years.~* Patients who have needed additions or alterations to their usual maintenance therapy for COPD due to worsening symptoms within 1 month prior to and during screening~* Treatment with depot corticosteroids within 6 weeks, or other systemic corticosteroids within 4 weeks, prior to screening. (Patients maintained on an equivalent of 5 mg prednisone per day for at least 3 months prior to screening are allowed.)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): glycopyrronium/formoterol fumarate 7.2/4.8 μg per actuation, twice daily
- Active comparator (Type: ACTIVE_COMPARATOR): umeclidinium/vilanterol 62.5/ 25μg per inhalation, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Birth male who identifies as male and reports sexual contact with another male~* Received an HIV negative test result from a participating clinic/recruitment site~* Unprotected anal sex with another male in the last 6 months~* Ability to read English at 8th grade level~Exclusion Criteria:~* HIV positive~* Female or Transgender~* No email address for contact~* Currently in a monogamous relationship lasting longer than 6 months~* Participated in previous versions of KIU!

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 29 Years
- Healthy Volunteers: t

Study Arms:
- Keep It Up! Intervention (Type: EXPERIMENTAL): The KIU! intervention is a multi-media online HIV prevention program developed specifically for young (18-29 years old) men who have sex with men (MSM) who recently tested HIV negative. Intervention content includes discussions of community involvement, scenarios on hooking-up online, communication skills in relationships (including negotiating safer sex), condom use, HIV knowledge, and HIV/STI risks. Information is presented in various formats like games, animation, and videos to address gaps in HIV knowledge, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors. The intervention is completed across three sessions, done at least 24 hours apart (i.e. at least 3 days), and takes about 2 hours total to complete.
- HIV Knowledge Control (Type: ACTIVE_COMPARATOR): The control condition reflects HIV information that is currently available on many websites so as to understand how the KIU! intervention improves upon what is currently available online. It is not tailored to YMSM, non-interactive, and focused on HIV/STI knowledge. The control is completed across three sessions done at least 24 hours apart (i.e. at least 3 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has chronic genotype 1 Hepatitis C infection~Exclusion Criteria:~* Has not tolerated previous course of peg-IFN and ribavirin~* Has HIV~* Has Hepatitis B~* Has a history of clinically significant medical condition that may interfere with the study (e.g., stroke or chronic seizures or major neurological disorder) or is contraindicated for treatment with peg-IFN and ribavirin

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Vaniprevir 200 mg + peg-IFN + ribavirin (Type: EXPERIMENTAL): Participants will receive vaniprevir 100 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
- Vaniprevir 600 mg + peg-IFN + ribavirin (Type: EXPERIMENTAL): Participants will receive vaniprevir 300 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
- Vaniprevir 1200 mg + peg-IFN + ribavirin (Type: EXPERIMENTAL): Participants will receive vaniprevir 600 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
- Placebo + peg-IFN + ribavirin (Type: PLACEBO_COMPARATOR): Participants will receive placebo twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* be at least 18 years of age of either gender and any race~* have at least a two-year history of moderate-to-severe ragweed-induced allergic conjunctivitis based on principal investigator's judgement~* have a positive skin prick test to ragweed pollen within the past year of screening~Exclusion Criteria:~* known contraindication or hypersensitivities to any components of the investigational product medication or components~* history of uveitis, blepharitis, dry eye syndrome, herpes simplex keratitis, or herpes zoster keratitis;~* presence of any ocular infection (bacterial, viral, or fungal) or active ocular inflammation (e.g., follicular conjunctivitis, allergic conjunctivitis) within 14 days prior to screening~* presence of any chronic ocular degenerative condition or ocular inflammation that, in the opinion of the investigator, is likely to worsen over the course of the clinical trial;~* diagnosis of moderate-to-severe pinguecula or pterygium (particularly if it results in chronic erythema), Stevens-Johnson Syndrome, ocular cicatricial pemphigoid, mucous membrane pemphigoid, significant conjunctival scarring, chemical burn, herpetic or neurotrophic keratitis, Cryopyrin Associated Periodic Syndrome (CAPS), or keratoconus~* woman of childbearing potential who is pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reproxalap Ophthalmic Solution (0.25%) (Type: ACTIVE_COMPARATOR): None
- Vehicle Ophthalmic Solution (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete